DB
CNSP icon

Danske Bank’s CNS Pharmaceuticals CNSP Stock Holding History

Danske Bank’s Portfolio CNSP Stock Details CNSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2 Hold
1
– – ﹤0.01% 1138
2025
Q4 		$5 Hold
1
– – ﹤0.01% 1502
2025
Q3 		$9 Buy
+1
New +$8 ﹤0.01% 1420
2025
Q1 		– Hold
0
– – – 1392
2024
Q4 		– Hold
0
– – – 1463
2024
Q3 		– Hold
0
– – – 1622

Other funds holding CNSP

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SIS
Sound Income Strategies Ft Lauderdale, Florida $2.23B AUM 11.22% 1-Year Est. Return
BC
Barrett & Company Providence, Rhode Island $357M AUM 22.45% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return

Danske Bank's CNSP Position: Q1 2026 in Review

Danske Bank held its CNS Pharmaceuticals (CNSP) position steady in Q1 2026 at 1 share worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #1138.

Danske Bank first reported a position in CNSP in Q3 2025 and has held it in 3 quarters since. The position peaked at $9 in Q3 2025. 12 funds tracked by Wall St. Rank hold CNSP as of Q1 2026.

  • Danske Bank held 1 share of CNS Pharmaceuticals worth $2 as of Q1 2026.
  • Danske Bank left its CNS Pharmaceuticals share count unchanged in Q1 2026.
  • CNS Pharmaceuticals made up ﹤0.01% of Danske Bank's portfolio in Q1 2026, its #1138 holding.
  • Danske Bank first reported a position in CNS Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Danske Bank's CNS Pharmaceuticals position peaked at $9 in Q3 2025.
  • 12 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q1 2026.

Based on Danske Bank's 13F filing for Q1 2026, filed 12 May 2026.